Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGN-P1 diimine
- Development stage
- Preclinical
- Lead developer
- ImmunoGen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
IGN-P1 diimine is a DNA cross-linking indolino-benzodiazepine (IGN) dimer payload developed by ImmunoGen for use in antibody-drug conjugates (ADCs). It is the diimine analog of DGN549 (also known as IGN-P1), which is a mono-imine DNA alkylator. Unlike DGN549, which alkylates DNA without cross-linking, IGN-P1 diimine functions by forming interstrand cross-links in the DNA minor groove. This mechanism typically results in high cytotoxicity but may offer a narrower therapeutic index and reduced bystander killing compared to mono-imine alkylators. In preclinical studies, IGN-P1 diimine was conjugated to antibodies targeting folate receptor-alpha (FRα) and EpCAM, demonstrating potent anti-tumor activity in xenograft models, including endometrial cancer. However, comparative studies suggested that the mono-imine version (DGN549) provided superior efficacy and tolerability.
- Other names
- indolino-benzodiazepine diimine
02
Targets
DNA-G-N2 (Duplex DNA guanine N2 (minor groove))
Beyond the preview
Go deeper on IGN-P1 diimine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGN-P1 diimine.